Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 01, 2024

Cadonilimab Plus Chemotherapy With or Without Bevacizumab as a First-Line Treatment for Recurrent or Metastatic Cervical Cancer

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study
Clin. Cancer Res 2024 Apr 15;30(8)1501-1508, H Lou, H Cai, X Huang, G Li, L Wang, F Liu, W Qin, T Liu, W Liu, ZM Wang, B Li, Y Xia, J Wang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading